Prevention of Ovarian Cancer: Intraepithelial Neoplasia

Clinical Cancer Research

Volumn 9, Issue 1, 2003, Pages 20-30

  Brewer, Molly A ^a,c   Johnson, Karen ^b   Follen, Michele ^c,d   Gershenson, David ^c   Bast, Robert ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; ORAL CONTRACEPTIVE AGENT; RETINOID;

ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; DRUG MECHANISM; FEMALE; GYNECOLOGIC CANCER; HIGH RISK POPULATION; NONHUMAN; OVARY CANCER; PHENOTYPE; PRECANCER; PRIORITY JOURNAL; PUBLICATION; SHORT SURVEY; UTERINE CERVIX CARCINOMA IN SITU;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLOOXYGENASE 2; ENZYME INHIBITORS; EPITHELIUM; FEMALE; GENETIC MARKERS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; OVARY; PRECANCEROUS CONDITIONS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RETINOIDS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0037240119     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: None     Document Type: Article

References (107)

1. Hoskins, W. J. Prospective on ovarian cancer: why prevent? J. Cell. Biochem. Suppl., 23: 189–199, 1995.
2. Kelloff, G. J., Boone, C. W., Crowell, J. A., Nayfield, S. G., Hawk, E., Steele, V. E., Lubet, R. A., and Sigman, C. C. Strategies for Phase II cancer chemoprevention trials: cervix, endometrium, and ovary. J. Cell. Biochem. Suppl., 23: 1–9, 1995.
3. Dhingra, K. A Phase II chemoprevention trial design to identify surrogate endpoint biomarkers in breast cancer. J. Cell. Biochem. Suppl., 23: 19–24, 1995.
4. Casagrande, J. T., Pike, M. C., Ross, R. K., Louise, E. W., Roy, S., and Henderson, B. E. Incessant ovulation and ovarian cancer. Lancet, 2: 170–172, 1979.
5. Greene, M. H., Clark, J. W., and Blayney, D. W. The epidemiology of ovarian cancer. Semin. Oncol., 11: 209–226, 1984.
6. Hartge, P., Schiffman, M. H., Hoover, R., McGowan, L., Lesher, L., and Norris, H. J. A case-control study of epithelial ovarian cancer. Am. J. Obstet. Gynecol., 161: 10–16, 1989.
7. Hildreth, N. G., Kelsey, J. L., LiVolsi, V. A., Fischer, D. B., Holford, T. R., Mostow, E. D., Schwartz, P. E., and White, C. An epidemiologic study of epithelial carcinoma of the ovary. Am. J. Epidemiol., 114: 398–405, 1981.
8. Joly, J. D., Lilienfeld, A. M., Diamond, E. L., and Borss, I. D. J. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary. Am. J. Epidemiol., 99: 190–209, 1974.
9. Kvale, G., Heuch, I., Nilssen, S., and Beral, V. Reproductive factors and risk of ovarian cancer. A prospective study. Int. J. Cancer, 42: 246–251, 1988.
10. Mori, M., Harabuchi, I., Miyake, H., Casagrande, J. T., Henderson, B. E., and Ross, R. K. Reproductive, genetic, and dietary risk factors for ovarian cancer. Am. J. Epidemiol., 128: 771–777, 1988.
11. Whittemore, A. S., Harris, R., and Itnyre, J. Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. II. Invasive epithelial ovarian cancers in white women. Am. J. Epidemiol., 136: 1184–1203, 1992.
12. Franceschi, S., Parazzini, F., Negri, E., Booth, M., La Vecchia, C., Beral, V., Tzonou, A., and Trichopoulos, D. Pooled analysis of 3 European case-control studies of epithelial ovarian cancers. III. Oral contraceptive use. Int. J. Cancer, 49: 61–65, 1991.
13. Centers for Disease Control Cancer and Steroid Hormone Study. Oral contraceptive use and the risk of ovarian cancer. J. Am. Med. Assoc., 249: 1596–1599, 1983.
14. Rosenberg, L., Shapiro, S., Slone, D., Kaufman, D. W., Helmrich, S. P., Miettinen, O. S., Stolley, P. D., Rosenshein, M. B., Schottenfeld, D., and Engle, R. L., Jr. Epithelial ovarian cancer and combination oral contraceptives. J. Am. Med. Assoc., 247: 3210–3212, 1982.
15. Easton, D. F., Ford, D., and Bishop, D. T. Breast and ovarian cancer incidence in BRCA-1 mutation carriers. Breast Cancer Linkage Consortium. Am. J. Hum. Genet., 56: 265–271, 1995.
16. Berry, D., Parmigiani, G., Sanchez, J., Schildkraut, J., and Winer, E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA-1 based on family history. J. Natl. Cancer Inst. (Bethesda), 89: 227–238, 1997.
17. Struewing, J., Hartge, P., Wacholder, S., Baker, S., Berlin, M., McAdams, M., Timmerman, M., Brody, L., and Tucker, M. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336: 1401–1408, 1997.
18. Gershenson, D. M., Tortolero-Luna, G., Malpica, A., Baker, V. V., Whittaker, L., Johnson, E., and Mitchell, M. F. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet. Gynecol. Clin. N. Am., 23: 475–543, 1996.
19. Salazar, H., Godwin, A. K., Daly, M. B., Laub, P. B., Hogan, W. M., Rosenblum, N., Boente, M. P., Lynch, H. T., and Hamilton, T. C. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J. Natl. Cancer Inst. (Bethesda), 88: 1810–1820, 1996.
20. Scully, R. E. Pathology of ovarian cancer precursors. J. Cell. Biochem. Suppl., 23: 208–218, 1995.
21. Deligdisch, L., Miranda, C., Barba, J., and Gil, J. Ovarian dysplasia: nuclear texture analysis. Cancer (Phila.), 72: 3253–3257, 1993.
22. Deligdisch, L., Gil, J., Kerner, K., Wu, H. S., Beck, D., and Gershoni-Baruch, R. Ovarian dysplasia in prophylactic oophorectomy specimens, cytogenetic and morphometric correlations. Cancer (Phila.), 86: 1544–1550, 1999.
23. Puls, L., Powell, D., DePriest, P. D., Gallion, H. H., Hunter, J. E., Kryscio, R. J., and van Nagell, J. R., Jr. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadeno-carcinoma. Gynecol. Oncol., 47: 53–57, 1992.
24. Plaxe, S. C., Deligdisch, L., Dottino, P. R., and Cohen, C. J. Ovarian intraepithelial neoplasia demonstrated in patients with stage I ovarian carcinoma. Gynecol. Oncol., 38: 367–372, 1990.
25. Blaustein, A. Surface cells and inclusion cysts in fetal ovaries. Gynecol. Oncol., 12: 222–233, 1981.
26. Blaustein, A., Kantius, M., Kaganowicz, A., Pervez, N., and Well, J. Inclusions in ovaries of females aged day 1–30 years. Int. J. Gynecol. Pathol., 1: 145–153, 1982.
27. Lu, K., Garber, J., Cramer, D., Welch, W., Niloff, J., Schrag, D., Berkowitz, R., and Muto, M. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J. Clin. Oncol., 18: 2728–2732, 2000.
28. Stratton, J. F., Buckley, C. H., Lowe, D., Ponder, B. A. J., and UKCCCR Familial Ovarian Cancer Study Group. Comparison of prophylactic oophorectomy specimens from carriers and non-carriers of a BRCA1 or BRCA2 gene mutation. J. Natl. Cancer Inst. (Bethesda), 91: 626–628, 1999.
29. Barakat, R. R., Federici, M. G., Saigo, P. E., Robson, M. E., Offit, K., and Boyd, J. Absence of premalignant histologic, molecular or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer (Phila.), 89: 383–390, 2000.
30. Casey, M. J., Bewtra, C., Hoehne, B. S., Tatpati, A. D., Lynch, H. T., and Watson, P. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with non-carriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol. Oncol., 78: 278–287, 2000.
31. Roby, K. E., Taylor, C. C., Sweetwood, J. P., Cheng, Y., Pace, J. L., Tawfik, O., Persons, D. L., Smith, P. G., and Terranova, P. E. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis (Lond.), 21: 585–591, 2000.
32. Davies, B. R., Auersperg, N., Worsley, S. D., and Ponder, B. A. J. Transfection of rat ovarian surface epithelium with erb-B2/neu induces transformed phenotypes in vitro and the tumorigenic phenotype in vivo. Am. J. Pathol., 152: 297–306, 1998.
33. Fredrickson, T. N. Ovarian tumors of the hen. Environ. Health Perspect., 73: 35–51, 1987.
34. Rodriguez-Burford, C., Barnes, M. N., Berry, W., Partridge, E. E., and Grizzle, W. E. Immuno-histochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Gynecol. Oncol., 81: 373–379, 2001.
35. Berchuck, A., Rodriguez, G. C., Kamel, A., Dodge, R. K., Soper, J. T., Clarke-Pearson, D. L., and Bast, R. C., Jr. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol., 164: 669–674, 1991.
36. Berchuck, A., Kamel, A., Kerns, W. B., Kinney, R., Soper, R., Dodge, D. L., Clarke-Pearson, P., McKenzie, S., Yin, S., and Bast, R. C., Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087–4091, 1990.
37. Auersperg, N., Edelson, M. I., Mok, S. C., Johnson, S. W., and Hamilton, T. C. The biology of ovarian cancer. Semin. Oncol., 25: 281–304, 1998.
38. Henzen-Logmans, A. C., van der Burg, M. E. L., Foekens, J. A., Berns, P. M. J. J., Brussee, R., Fieret, J. H., Klijn, J. G. M., Chadha, S., and Rodenburg, C. J. Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study. J. Cancer Res. Clin. Oncol., 118: 303–307, 1992.
39. Harlozinska, A., Bar, J. K., Sobanska, E., and Goluda, M. Epidermal growth factor receptor and c-erbB-2 oncoproteins in tissue and tumor effusion cells of histopathologically different ovarian neoplasms. Tumor Biol., 19: 364–373, 1998.
40. Simpson, B. J. B., Phillips, H. A., Lessells, A. M., Langdon, S. P., and Miller, W. R. C-erb B growth-factor-receptor proteins in ovarian tumors. Int. J. Cancer, 64: 202–206, 1995.
41. Bartlett, J. M. S., Langdon, S. P., Simpson, B. J. B., Stewart, M., Katsaros, D., Sismondi, P., Love, S., Scott, W. N., Williams, A. R. W., Lessells, A. M., Macleod, K. G., Smyth, J. F., and Miller, W. R. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer, 73: 301–306, 1996.
42. Ross, J. S., Yang, F., Kallakury, B. V., Sheehan, C. E., Ambros, R. A., and Muraca, P. J. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am. J. Clin. Pathol., 11: 311–316, 1999.
43. Niikura, H., Sasano, H., Sato, S., and Yajima, A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. J. Gynecol. Pathol., 16: 60–68, 1997.
44. Bast, R. C., Puztai, L., Kerns, B. J., MacDonald, J. A., Jordan, P., Daly, L., Boyer, C. M., Mndolson, J., and Berchuk, A. Coexpression of the HER-2/neu (c-erbB2) gene product (p185) and the epidermal growth factor receptor (p170) on epithelial ovarian cancers and normal tissues. Hybridoma, 17: 313–321, 1998.
45. Campiglio, M., Ali, S., Knyazev, P. G., and Ullrich, A. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J. Cell. Biochem., 73: 522–532, 1999.
46. Matsumoto, Y., Ishiko, O., Deguchi, M., Nadagawa, E., and Ogita, S. Cyclo-oxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int. J. Mol. Med., 8: 31–36, 2001.
47. Rodriguez-Burford, C., Barnes, M. N., Oelschlager, D. K., Myers, R. B., Talley, L. I., Partridge, E. E., and Grizzle, W. E. Effects of nonsteroidal anti-inflammatory agents (NSAIDs) on ovarian carcinoma cell lines: Preclinical evaluation of NSAIDs as chemopreventive agents. Clin. Cancer Res. 8: 202–209, 2002.
48. Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., Ferrandina, G., Benedetti Panici, P., Mancuso, S., Neri, G., and Testa, J. R. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer, 64: 280–285, 1995.
49. Iwabuchi, H., Sakamoto, M., Sakunaga, H., Ma, Y. Y., Carcangiu, M. L., Pinkel, D., Yang-Feng, T. L., and Gray, J. W. Genetic analysis of benign, low-grade, and high-grade ovarian tumors. Cancer Res., 55: 6172–6180, 1995.
50. Bast, R. C., and Mills, B. F. Alterations in oncogenes, tumor suppressor genes, and growth factors associated with epithelial ovarian cancers. In: J. M. S. Bartlett (ed.), Ovarian Cancer, Methods and Protocols, Methods in Molecular Medicine, pp. 37–48. Totowa, NJ: Humana Press, Inc., 2000.
51. Shayesteh, L., Lu, Y., Kuo, W-L., Baldocchi, R., Godfrey, T., Collins, C., Pinkel, D., Powell, B., Mills, G. B., and Gray, J. W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 21: 99–102, 1999.
52. Hu, L., Zaloudek, C., Mills, G. B., Gray, J., and Jaffe, R. B. In vivo and in vitro ovarian carcinoma growth inhibition by a phophatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res., 6: 880–886, 2000.
53. Berchuck, A., Kohler, M. F., Marks, J. R., Wiseman, R., Boyd, J., and Bast, R. C., Jr. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am. J. Obstet. Gynecol., 170: 246–252, 1994.
54. Centers for Disease Control Cancer and Steroid Hormone Study. The reduction in risk of ovarian cancer associated with oral contraceptive use. N. Engl. J. Med., 316: 650–655, 1987.
55. Weiss, N. S., Lyon, J. L., Liff, J. M., Vollmer, W. M., and Daling, J. R. Incidence of ovarian cancer in relation to the use of oral contraceptives. Int. J. Cancer, 28: 669–671, 1981.
56. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Epithelial ovarian cancer and combined oral contraceptives. Int. J. Epidemiol., 8: 538–545, 1989.
57. Rodriguez, G. C., Walmer, D. K., Cline, M., Krigman, H., Lessey, B. A., Whitaker, R. S., Dodge, R., and Hughes, C. L. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J. Soc. Gynecol. Invest., 5: 271–276, 1998.
58. Schildkraut, J. M., Calingaert, B., Marchbanks, P. A., Moorman, P. G., and Rodriguez, G. C. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J. Natl. Cancer Inst. (Bethesda), 94: 32–38, 2002.
59. Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., and Boyce, B. F. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat. Med., 2: 1132–1136, 1996.
60. Um, S-J., Lee, S-Y., Kim, E-J., Han, H-S., Koh, Y-M., Hong, K-J., Sin, H-S., and Park, J-S. Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett., 174: 127–134, 2001.
61. Zhang, D., Holmes, W. F., Wu, S., Soprano, D. R., and Soprano, K. J. Retinoids and ovarian cancer. J. Cell. Physiol., 185: 1–20, 2000.
62. Formelli, F., and Cleris, L. Synthetic retinoid fenretinamide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res., 53: 5374–5376, 1993.
63. Taylor, D. D., Taylor, C. G., Black, P. H., Jiang, C. G., and Chou, I. N. Alterations of cellular characteristics of a human ovarian teratocarcinoma cell line after in vitro treatment with retinoids. Differentiation, 43: 123–130, 1990.
64. DePalo, G., Veronesi, U., Camerini, T., Formelli, F., Mascotti, G., and Boni, C. Can fenretinamide protect women against ovarian cancer. J. Natl. Cancer Inst. (Bethesda), 87: 146–147, 1995.
65. De Palo, G., Mariani, L., Camerini, T., Marubini, E., Formelli, F., Pasini, B., Decensi, A., and Veronesi, U. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol. Oncol., 86: 24–27, 2002.
66. Guruswamy, S., Lightfoot, S., Gold, M. A., Hassan, R., Berlin, D., Ivey, R. T., and Benbrook, D. M. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J. Natl. Cancer Inst. (Bethesda), 93: 516-525, 2001.
67. Wu, S., Zhang, D., Donigan, A., Dawson, M. I., Soprano, D. R., and Soprano, K. J. Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth. J. Cell. Biochem., 68: 378-388, 1998.
68. Brewer, M., Utzinger, U., Li, Y., Atkinson, E. N., Satterfield, W., Auersperg, N., Richards-Kortum, R., Follen, M., and Bast, R. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman rhesus primate model for ovarian cancer chemopreventive agents. J. Biomed. Opt., 7: 20–26, 2002.
69. Wyllie, A. H. Apoptosis and carcinogenesis. Eur. J. Cell. Biol., 73: 189–197, 1997.
70. Zou, C. P., Kurie, J. M., Lotan, D., Zou, C. C., Hong, W. K., and Lotan, R. Higher potency of N-(4-hydroxyphenyl) retinamide than alltrans-retinoic acid in induction of apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res., 4: 1345–1355, 1998.
71. Supino, R., Crosti, M., Clerici, M., Warlters, A., Cleris, L., Zunino, F., and Formelli, F. Induction of apoptosis by fenretinide (4-HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int. J. Cancer, 65: 491–497, 1996.
72. Fanjul, A. N., Delia, D., Pierotti, M. A., Rideout, D., Yu, J. Q., Pfahl, M., and Qiu, J. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J. Biol. Chem., 271: 22441–22446, 1996.
73. Sheikh, M. S., Shao, Z. M., Li, X. S., Ordonez, J. V., Conley, B. A., Wu, S., Dawson, M. I., Han, Q. X., Chao, W. R., and Quick, T. N-(4-Hydroxyphenyl) retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis (Lond.), 16: 2477–2486, 1995.
74. Dabal, R., Boyer, C. M., Berchuck, A., Roberts, A., Roche, N., Sporn, M., and Bast, W. Synergistic inhibition of ovarian cancer cell proliferation by TGFβ and retinoic acid (RA) derivatives. Proc. Am. Assoc. Cancer Res., 36: 635, 1995.
75. Oridate, N., Suzuki, S., Higuchi, M., Mitchell, M., Hong, W., and Lotan, R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J. Natl. Cancer Inst. (Bethesda), 89: 1191–1198, 1997.
76. Berchuck, A., Rodriguez, G., Olt, G. J., Whitaker, R., Boente, M. P., Arrick, B. A., Clarke-Pearson, D. L., and Bast, R. C., Jr. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-β Am. J. Obstet. Gynecol., 166: 676–684, 1992.
77. Jakowlew, S. B., Moody, T. W., and Mariano, J. M. Transforming growth factor-β receptors in human cancer cell lines: analysis of transcript, protein and proliferation. Anticancer Res., 17: 1849–1860, 1997.
78. Schneider, S. L., Gollnick, S. O., Grande, C., Pazik, J. E., and Tomasi, T. B. Differential regulation of TGF-β 2 by hormones in rat uterus and mammary gland. J. Reprod. Immunol., 32: 125-144, 1996.
79. Lindstrom, P., Bergh, A., Holm, I., and Damber, J. E. Expression of transforming growth factor-β 1 in rat ventral prostate and Dunning R3327 PAP prostate tumor after castration and estrogen treatment. Prostate, 29: 209–218, 1996.
80. Rodriguez, G. C., Nimesh, N. P., Lee, K. L., Bentley, R. C., Walmer, D. K., Cline, M., Whitaker, R. S., Isner, P., Berchuck, A., Dodge, R. K., and Hughes, C. L. Progestin-induced apoptosis in the macaque ovarian epithelium: differential regulation of transforming growth factor-β. J. Natl. Cancer Inst. (Bethesda), 94: 50–60, 2002.
81. Auersperg, N., Maclaren, I. A., and Kruk, P. A. Ovarian surface epithelium: autonomous production of connective tissue-type extracellular matrix. Biol. Reprod., 44: 717–724, 1991.
82. Parrott, J. A., Nilsson, E., Mosher, R., Magrane, G., Albertson, D., Pinkel, D., Gray, J., and Skinner, M. K. Stroma-epithelial interactions in the progression of ovarian cancer: influence and source of stromal cells. Mol. Cell. Endocrinol., 175: 29–39, 2001.
83. Parrott, J. A., Kim, G., Mosher, R., and Skinner, M. K. Expression and action of keratinocyte growth factor (KGF) in normal ovarian surface epithelial and ovarian cancer. Mol. Cell. Endocrinol., 167: 77–87, 2000.
84. Parrott, J. A., Mosher, R., Kim, G., and Skinner, M. K. Autocrine interactions of keratinocyte growth factor, hepatocyte growth factor, and kit-ligand in the regulation of normal ovarian surface epithelial cells. Endocrinology, 141: 2532–2539, 2000.
85. Wong, A. S. T., Pelech, S. L., Woo, M., Yim, G., Rosen, B., Ehlen, T., Leung, P., and Auersperg, N. Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis? Oncogene, 20: 1318–1328, 2000.
86. Auersperg, N., Maines-Bandiera, S., Dyck, H. G., and Kruk, P. A. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab. Investig., 71: 510–518, 1994.
87. Mourant, J. R., Bigio, I. J., Boyer, J., Conn, R. L., Johnson, T., and Shimada, T. Spectroscopic diagnosis of bladder cancer with elastic light scattering. Lasers Surg. Med., 17: 350–357, 1995.
88. Ge, Z., Schomacker, K. T., and Nishioka, N. S. Identification of colonic dysplasia and neoplasia by diffuse reflectance spectroscopy and pattern recognition techniques. Appl. Spectrosc., 52: 833–345, 1998.
89. Koenig, F., Larne, R., Enquist, H., McGovern, F. J., Schomacker, K. T., Kollias, N., and Deutsch, T. F. Spectroscopic measurement of diffuse reflectance for enhanced detection of bladder carcinoma. Urology, 51: 342–345, 1998.
90. Backman, V., Wallace, M., Perelman, L. T., Arendt, J. T., Gurjar, R., Muller, M. G., Zhang, Q., Zonios, G., Kline, E., McGillican, T., Shapshay, S., Valdez, T., Badizadegan, K., Crawford, J. M., Fitzmaurice, M., Kabani, S., Levin, H. S., Seiler, M., Dasari, R. R., Itzkan, I., Van Dam, J., and Feld, M. S. Detection of preinvasive cancer cells. Nature (Lond.), 406: 35-36, 2000.
91. Richards-Kortum, R., and Sevick-Muraca, E. Quantitative optical spectroscopy for tissue diagnosis. Annu. Rev. Phys. Chem., 47: 555– 606, 1996.
92. Mahadevan-Jansen, A., and Richards-Kortum, R. Raman spectroscopy for the detection of cancers and precancers. J. Biomed. Opt., 1: 31–70, 1996.
93. Bigio, I. J., and Mourant, J. R. Ultraviolet and visible spectroscopies for tissue diagnostics: fluorescence spectroscopy and elastic-scattering spectroscopy. Phys. Med. Biol., 42: 803–814, 1997.
94. Chance, B. Metabolic heterogeneities in rapidly metabolizing tissues. J. Appl. Cardiol., 4: 207–221, 1989.
95. Gulledge, C. J., and Dewhirst, M. W. Tumor oxygenation: a matter of supply and demand. Anticancer Res., 16: 741-750, 1996.
96. Brewer, M., Utzinger, U., Silva, E., Gershenson, D., Bast, R. C., Jr., Follen, M., and Richards-Kortum, R. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg. Med., 29: 128–135, 2001.
97. Brewer, M., Utzinger, U., Silva, E., Gershenson, D., Bast, R. C., Jr., Follen, M., Wharton, J. T., and Richards-Kortum, R. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. Cancer Epidemiol. Biomark. Prev., 10: 889–893, 2001.
98. Blume-Jensen, P., and Hunter, T. Oncogenic kinase signaling. Nature (Lond.), 411: 355–365, 2001.
99. Slichenmyer, W. J., and Fry, D. W. Anticancer therapy targeting the ErbB family of receptor tyrosine kinases. Semin. Oncol., 28: 67–79, 2001.
100. Moulder, S. L., Yakes, M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., and Arteaga, C. L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 61: 8887–8895, 2001.
101. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946–1952, 2000.
102. Ness, R. B., and Cottreau, C. Possible role of ovarian epithelial inflammation in ovarian cancer. J. Natl. Cancer Inst. (Bethesda), 91: 1459–1467, 1999.
103. Williams, A. R. W. Pathological assessment of ovarian cancer. In: J. M. S. Bartlett (ed.), Ovarian Cancer, Methods and Protocols, Methods in Molecular Medicine, pp. 49–60. Totowa, NJ: Humana Press, Inc., 2000.
104. Zheng, J., Benedict, W. F., Xu, H. J., Hu, S. X., Kim, T. M., Velicescu, M., Wan, M., Cofer, K. F., and Dubeau, L. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas. J. Natl. Cancer Inst. (Bethesda), 87: 1146–1153, 1995.
105. Liotta, L., and Petricoin, E. F. Molecular profiling of human cancer. Nat. Rev. Genet., 1: 48–56, 2000.
106. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359: 572–577, 2002.
107. Liotta, L., Kohn, L. C., and Petricoin, E. F. Clinical proteomics, personalized molecular medicine. J. Am. Med. Assoc., 286: 2211–2214, 2001.